

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6389413

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	ASSIGNMENT
RESUBMIT DOCUMENT ID:	506292134
CONVEYING PARTY DATA	
Name	Execution Date
Bin-Feng Li	09/24/2020
RECEIVING PARTY DATA	
Name:	AGNO PHARMA USA
Street Address:	752 56TH STREET
Internal Address:	1ST FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	11220
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16899641
Application Number:	16899645
Application Number:	16899654
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (650) 839-5080
Email:	apsi@fr.com
Correspondent Name:	CALEB A. BATES
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	46696-0015005; -006; -007
NAME OF SUBMITTER:	SUZANNE O'NEILL
SIGNATURE:	/Suzanne C. O'Neill/
DATE SIGNED:	11/06/2020
Total Attachments: 5	

source=46696-001500 Notice of Recordation#page2.tif
source=46696-001500 Notice of Recordation#page3.tif
source=46696-001500 Notice of Recordation#page4.tif
source=46696-001500 Notice of Recordation#page5.tif
source=46696-001500 Notice of Recordation#page6.tif



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

November 05, 2020

PTAS

CALEB A. BATES
FISH & RICHARDSON P.C.
P.O.BOX 1022
MINNEAPOLIS, MN 55440-1022



506292134

United States Patent and Trademark Office
Notice of Non-Recordation of an Assignment Document

The enclosed document has been examined and found non-recordable by the Assignment Recordation Branch of the U.S. Patent and Trademark Office. The reason(s) for non-recordation are stated below:

1. The document submitted is not legible for recording purposes.

Documents being resubmitted for recordation must reflect the corrected information to be recorded, the Document ID number referenced above and all pages from this submitted document. The original date of filing of this assignment document will be maintained if resubmitted with the appropriate correction(s) by **Tuesday, January 5, 2021**, as outlined under 37 CFR 3.51. The resubmitted document must include a stamp with the official date of receipt under 37 CFR 3. Applicants may use the certified procedures under 37 CFR 1.8 or 1.10 for resubmission of the returned papers if they desire to have the benefit of the date of deposit in the United States Postal Service.

To file the resubmission electronically, navigate to the EPAS website at <http://epas.uspto.gov>, click the Start Resubmission button and enter the following information:

Document ID: 506292134
Access Code: XGQKQ3Z57T36OK

To file the resubmission in paper, send documents to: U.S. Patent and Trademark Office, Mail Stop: Assignment Recordation Branch, P.O. BOX 1450, Alexandria, VA 22313. If you have any questions regarding this notice, you may contact the Assignment Recordation Branch at 571-272-3350.

STEFANIE BRYCE
ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6338882

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Bin-Feng Li	09/24/2020
RECEIVING PARTY DATA	
Name:	AGNO PHARMA USA
Street Address:	752 56TH STREET
Internal Address:	1ST FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	11220
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16899641
Application Number:	16899645
Application Number:	16899654
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (650) 839-5080
Email:	apsi@fr.com
Correspondent Name:	CALEB A. BATES
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	46696-0015005; -006; -007
NAME OF SUBMITTER:	SUZANNE C. O'NEILL
SIGNATURE:	/Suzanne C. O'Neill/
DATE SIGNED:	10/07/2020
Total Attachments: 3	
source=46696-0015005 Assignment - Bin-Feng to Agno#page1.tif	
source=46696-0015005 Assignment - Bin-Feng to Agno#page2.tif	

ASSIGNMENT

For valuable consideration, the receipt of which I acknowledge, and intending to be bound legally, I, BIN-FENG LI, assign to AGNO PHARMA USA, a corporation formed under the laws of Delaware and having a principal place of business at 752 56th Street, 1st Floor, New York, NY 11220, and its successors, transferees, and assignees (collectively the "Assignee"), all of my right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in patent applications that names me as inventor, along with co-inventors Kevin McGee, Scott E. Zook, Andrew Carr, and Thierry Bonnaud, as described in Schedule A.

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

I authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in my name or in the Assignee's name.

I represent and warrant that I have the right and power to make this Assignment and that I have not made and will not make any other assignment that conflicts with this Assignment.

I will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.



Bin-Feng Li

Date: 09/24/2020

ML

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: AGNO PHARMA USA

Signature: 

Date: Sep 26, 2020

Name: James J. Chen

Title: President

Schedule A

Matterid	Client Ref	Title	Filed	Appln	Issue	Patent No.	Country
46696-0015001	033.US2.REG	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	15/338,214	9/4/2018	10,065,952	UNITED STATES
46696-0015002	033.US3.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	7/23/2018	16/043,059			UNITED STATES
46696-0015003	033.US4.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	3/6/2019	16/293,728			UNITED STATES
46696-0015004	033.US5.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/24/2019	16/662,346			UNITED STATES
46696-0015005	033.US6.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	6/12/2020	16/899,641			UNITED STATES
46696-0015006	033.US7.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	6/12/2020	16/899,645			UNITED STATES
46696-0015007	033.US8.CON	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	6/12/2020	16/899,654			UNITED STATES
46696-0015AE1	033.AE1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	P6000571/2018			UNITED ARAB EMIRATES
46696-0015AU1	033.AU1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	2016343633			AUSTRALIA
46696-0015BH1	033.BH1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	BP 68/2018			BAHRAIN
46696-0015BR1	033.BR1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	BR11201800846 0-3			BRAZIL
46696-0015CA1	033.CA1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	3002074			CANADA
46696-0015CL1	033.CL1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	2018-1089			CHILE
46696-0015CN1	033.CN1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	201680072826.6			CHINA
46696-0015CO1	033.CO1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	NC2018/0004589			COLOMBIA
46696-0015DZ1	033.DZ1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	180226			ALGERIA
46696-0015EA1	033.EA1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	201890852			EURASIA
46696-0015EG1	033.EG1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	PCT/710/2018			EGYPT
46696-0015EP1	033.EP1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	16794479.2			EUROPEAN PATENT CONVENTION
46696-0015HK1	033.HK1.EPO (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	19119796.1			HONG KONG
46696-0015ID1	033.ID1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	PID201803123			INDONESIA
46696-0015IL1	033.IL1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	258732			ISRAEL
46696-0015IN1	033.IN1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	201817015975			INDIA
46696-0015JO1	033.JO1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	4/16/2018	35/2018			JORDAN
46696-0015JP1	033.JP1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	2018-521548			JAPAN
46696-0015KR1	033.KR1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	10-2018-7014815			SOUTH KOREA
46696-0015KW1	033.KW1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	PCT/17/2018			KUWAIT
46696-0015MX1	033.MX1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	MX/a/2018/00513 6			MEXICO
46696-0015MY1	033.MY1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	PI2018000569			MALAYSIA
46696-0015NZ1	033.NZ1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	742006			NEW ZEALAND
46696-0015OM1	033.OM1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	OM/P/2018/0010 6			OMAN
46696-0015P01	033.US1.PRO	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/30/2015	62/249,074			UNITED STATES
46696-0015PE1	033.PE1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	627-2018			PERU
46696-0015PH1	033.PH1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	1-2018-500900			PHILIPPINES
46696-0015QA1	033.QA1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	QA/201804/0017 0			QATAR
46696-0015SA1	033.SA1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	518391477			SAUDI ARABIA
46696-0015SG1	033.SG1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	11201803408P			SINGAPORE
46696-0015TH1	033.TH1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	1801002488			THAILAND
46696-0015TN1	033.TN1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	TN2018/0121			TUNISIA
46696-0015VN1	033.VN1.PCT (MTPC)	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	1-2018-02035			VIET NAM
46696-0015WO1	033.WO1	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	PCT/US2016/059 306			WIPO
46696-0015ZA1	033.ZA1.PCT	VALBENZAZINE SALTS AND POLYMORPHS THEREOF	10/28/2016	2018/02610			SOUTH AFRICA